Our pipeline

Pipeline—creating tomorrow's vaccines today

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. At Novavax, our passion is helping to protect the health of people everywhere, so we are working to build a strong first line of defense against infectious diseases like COVID, influenza and malaria worldwide. 

Novavax continues to optimize preclinical candidates, including a new approach to H5N1 bird flu vaccination. In addition, we are seeking to expand our core technology to new targets and novel applications including mucosal vaccination and high-density nanoparticles. We continue to evaluate the potential of Matrix-MTM to augment immune responses to new and existing vaccines, including marketed products. We are conducting a prioritization review of our preclinical candidates to inform future early-stage clinical study investments to advance Novavax's product pipeline.

Our pipeline

Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.

Our Matrix-M adjuvant technology

Matrix-M adjuvant

Investigational vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.

Learn more about our technology platform

Vaccines in Novavax Pipeline and Status
Therapeutic area
Candidate
Adjuvant Technology
Phase of trial
Authorized use
   
Preclinical
Phase 1
Phase 2
Phase 3
 
Novavax Clinical/Commercial Stage
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine
Matrix-M™ adjuvant
    
 
Authorized1
Novavax Clinical Stage
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
Matrix-M™ adjuvant
  
 
Phase 2
 
Novavax Clinical Stage
Respiratory diseases
Seasonal influenza
Influenza vaccine (Older Adults)
Matrix-M™ adjuvant
  
 
Phase 2
 
Developed and distributed by Oxford University and Serum Institute of India, using licensed Matrix-M technology
Parasitic diseases
Malaria
R21/Matrix-M
Matrix-M™ adjuvant
    
 
Authorized2
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine
 
Authorized1
Matrix-M™ adjuvant
Novavax Clinical/Commercial Stage
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
 
Phase 2
Matrix-M™ adjuvant
Novavax Clinical Stage
Respiratory diseases
Seasonal influenza
Influenza vaccine (Older Adults)
 
Phase 2
Matrix-M™ adjuvant
Novavax Clinical Stage
Parasitic diseases
Malaria
R21/Matrix-M
 
Authorized2
Matrix-M™ adjuvant
Developed and distributed by Oxford University and Serum Institute of India, using licensed Matrix-M technology

Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax™; and Nuvaxovid™, authorized in the U.S. under trade name, Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula); and authorized in the EU under the trade name Nuvaxovid JN.1.  Authorization information can be found by country at https://novavaxcovidvaccine.com.


Authorized in Ghana, Nigeria, Central African Republic, Côte d'Ivoire and Burkina Faso; Commercialized by Serum Institute of India and granted prequalification by the WHO.

What we do

From the diseases that we're focused on to the details of our scientific approach

Who we are

Novavax is powered by global collaborations